McNicoll Lewis & Vlak Starts Alnylam Pharmaceuticals (ALNY) at Buy; Investing in the Next Leap of Human Therapeutics with RNA Interference (RNAi)
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $228.65 +0.67%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
McNicoll Lewis & Vlak initiates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Buy. PT $15.
MLV analyst says, "We would invest in ALNY for its focused pipeline and RNAi targeting large markets with the availability for early biomarkers of efficacy. Under the core product strategy, known as 5x15, ALNY intends to advance five RNAi therapeutic candidates by 2015. ALNY is currently advancing three core programs: ALN-TTR, the most advanced in clinical development, for the treatment of transthyretin-mediated amyloidosis, or ATTR; ALN-PCS for the treatment of severe hypercholesterolemia; and ALN-HPN for the treatment of refractory anemia."
For more ratings news on Alnylam Pharmaceuticals click here and for the rating history of Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $9.56 yesterday.
MLV analyst says, "We would invest in ALNY for its focused pipeline and RNAi targeting large markets with the availability for early biomarkers of efficacy. Under the core product strategy, known as 5x15, ALNY intends to advance five RNAi therapeutic candidates by 2015. ALNY is currently advancing three core programs: ALN-TTR, the most advanced in clinical development, for the treatment of transthyretin-mediated amyloidosis, or ATTR; ALN-PCS for the treatment of severe hypercholesterolemia; and ALN-HPN for the treatment of refractory anemia."
For more ratings news on Alnylam Pharmaceuticals click here and for the rating history of Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $9.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $256 at Wells Fargo
- BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
- Evercore ISI Starts Alvotech SA (ALVO) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
